Loading...
Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) postdocetaxel. Preclinical studies...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Libertas Academica
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3813614/ https://ncbi.nlm.nih.gov/pubmed/24179414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S11670 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|